Michael Klim Illness: CIDP Diagnosis, Symptoms and Life Now

Six Olympic medals don’t shield you from a rare disease. When former Australian swimmer Michael Klim began experiencing chronic ankle problems and back pain in 2019, the sports world assumed he was just feeling the toll of a legendary career. By June 2020, the six-time Olympic medallist was on crutches. The diagnosis that followed—chronic inflammatory demyelinating polyneuropathy, or CIDP—would redefine what his comeback looked like.

Diagnosis Year: 2020 · Condition: CIDP · Type: Rare autoimmune disorder · Targets: Peripheral nerves and myelin · Autobiography: 2024

Five key facts anchor the timeline of Michael Klim’s CIDP journey: a 2019 symptom onset, a 2020 diagnosis, mobility assistance required by June 2020, public disclosure through media outlets, and an ongoing advocacy foundation partnership with Australian Red Cross Lifeblood.

The table below consolidates verified facts about Klim’s CIDP diagnosis, Olympic achievements, and current advocacy work.

What is the cause of CIDP disease?

CIDP—chronic inflammatory demyelinating polyneuropathy—is a rare autoimmune disorder that attacks the peripheral nervous system. The condition specifically targets the myelin sheath, the insulating layer surrounding nerve fibers, according to Gold Coast Health Queensland (regional public health authority).

When the immune system mistakenly attacks myelin, nerve signal transmission slows or fails entirely. Patients experience progressive muscle weakness, typically starting in the legs, along with sensory disturbances including numbness or loss of feeling. The National Institute of Neurological Disorders and Stroke describes the mechanism as “inflammatory demyelinating polyneuropathy” affecting the peripheral nerves’ ability to carry signals between the brain, spinal cord, and muscles.

Autoimmune attack on myelin

The myelin sheath functions like insulation on an electrical wire. When inflammatory processes strip this insulation away, nerves lose their ability to conduct impulses efficiently. In CIDP, this demyelination occurs progressively, explaining why Klim experienced increasing mobility difficulties rather than sudden onset.

Gold Coast Health Queensland explains that IVIG (intravenous immunoglobulin) therapy helps reduce inflammation and maintain muscle function by modulating the immune response. This treatment approach addresses the underlying autoimmune process rather than just managing symptoms.

Peripheral nerve damage

The peripheral nervous system encompasses all nerves outside the brain and spinal cord. CIDP damages these peripheral nerves, causing the weakness and sensory loss Klim described experiencing—particularly in his legs, where he lost function from the knees down and sensation in both feet, according to Swimming World Magazine (established swimming journalism outlet).

What does Michael Klim do now?

Three years after his diagnosis, Michael Klim traded competition lanes for advocacy corridors. Instead of chasing world records, the seven-time world champion now runs the Klim Foundation (patient advocacy organization founded 2021), working alongside entrepreneur Michelle Owen to raise CIDP awareness across Australia.

Advocacy work

The foundation’s 2026 priorities focus on three areas: connecting directly with CIDP patients and families, expanding support services nationwide, and increasing education among healthcare professionals to accelerate diagnosis times. Klim partners with Australian Red Cross Lifeblood for broader awareness campaigns, using his athletic profile to shine light on a condition that often goes undiagnosed for months or years.

His public speaking includes interviews on The Sunday Telegraph and Channel Ten’s The Project where he first disclosed his diagnosis publicly, breaking a two-year silence. Ian Thorpe, his close friend and fellow Olympic champion, referred to Owen as Klim’s “human walking stick”—a nod to her caretaking role during his most difficult recovery period.

Post-swimming career

At 48 years old as of 2026, Klim reports feeling the best he has in years, a remarkable turnaround from June 2020 when he required crutches or a walking stick to move, according to Now to Love (Australian celebrity news outlet). He appeared on ABC’s Australian Story for its 30th season premiere on February 2, 2026, sharing his full journey from symptom onset through rehabilitation.

What is the life expectancy of a person with CIDP?

CIDP is not typically fatal. Unlike some neurological conditions, most patients with proper diagnosis and treatment maintain normal life expectancy. The condition affects quality of life and mobility but responds to therapy in many cases.

Prognosis factors

Treatment response varies significantly among CIDP patients. Those who respond well to IVIG therapy or other immunomodulatory treatments can stabilize or even improve over time. Klim’s case represents a positive trajectory—he regained sufficient function to walk unaided and report feeling his best in years.

The key variables affecting prognosis include: age at diagnosis, how quickly treatment began after symptom onset, individual response to therapy, and whether any permanent nerve damage occurred before treatment commenced. Early intervention generally correlates with better functional outcomes.

Long-term outlook

Gold Coast Health Queensland notes that ongoing management typically allows CIDP patients to maintain independence. Klim’s treatment protocol combines IVIG with massage, cupping, acupuncture, a TENS machine, special orthotics, and leg braces to address his specific deficits including drop foot and sensory loss.

What this means: CIDP requires individualized management, and patients should work closely with neurologists to find the right treatment combination rather than expecting uniform outcomes.

What are the red flags of CIDP?

Recognizing CIDP early depends on identifying its characteristic symptom pattern. The condition typically announces itself through progressive weakness and sensory changes that don’t follow a typical injury or overuse pattern.

Early symptoms

The earliest signs include:

• Progressive leg weakness, often bilateral
• Numbness or tingling in hands and feet
• Difficulty with balance and walking
• Loss of fine motor skills (buttoning shirts, writing)
• Fatigue disproportionate to activity level

Klim’s initial symptoms in 2019 manifested as chronic ankle problems and degenerative back issues—misleading presentations that initially delayed proper diagnosis. Many patients report similar confusion, visiting multiple specialists before neurological testing reveals CIDP.

Diagnosis triggers

Definitive CIDP diagnosis requires nerve conduction studies, MRI imaging, and sometimes lumbar puncture or muscle biopsy. Klim’s official website (primary source) documents his extensive diagnostic journey including all three testing modalities. The process confirmed peripheral nerve damage consistent with demyelination. Michael Klim’s battle with CIDP is a stark reminder that even elite athletes aren’t immune to serious health issues, as detailed in this article Who called me Australia.

Clinicians look for evidence of demyelination on nerve conduction velocity tests, spinal MRI showing nerve root enhancement, and elevated protein in cerebrospinal fluid. Klim underwent this full workup before beginning IVIG treatment.

What is CPID autoimmune disease?

The terminology requires clarification: CPID is not the standard medical term. The correct designation is CIDP—chronic inflammatory demyelinating polyneuropathy. The “P” stands for polyneuropathy (affecting multiple nerves), not “disease.”

Definition of CIDP

CIDP represents the chronic form of Guillain-Barré syndrome. While Guillain-Barré typically presents acutely and may resolve, CIDP persists for months or years, requiring ongoing management rather than acute intervention alone.

The condition falls into a category of autoimmune neuropathies where the immune system chronically attacks peripheral nerve myelin. Treatment aims to suppress inflammatory activity and support nerve regeneration where possible.

Chronic Inflammatory Demyelinating Polyneuropathy

“Chronic” indicates symptoms lasting more than eight weeks, distinguishing CIDP from acute inflammatory demyelinating polyneuropathy. “Inflammatory” describes the immune mechanism driving myelin damage. “Demyelinating” identifies the specific target—nerve insulation. “Polyneuropathy” means multiple nerves are affected simultaneously.

Gold Coast Health Queensland classifies CIDP as rare, affecting an estimated 1-2 per 100,000 people annually. The rarity itself creates diagnostic challenges—many physicians never encounter a case during their careers.

The pattern: CIDP’s rarity means that delayed diagnosis remains common, making public awareness campaigns like Klim’s valuable for earlier intervention.

For Australian patients facing CIDP diagnosis, the Klim Foundation offers what Klim wished he’d had: a centralized resource for information, peer connection, and healthcare professional education. The foundation’s expansion plans for 2026 directly address the isolation that rare disease diagnosis creates.

Related reading: Narcissistic Personality Disorder · How to Get Rid of a Sinus Infection

Frequently asked questions